Choosing appropriate patients with systemic sclerosis for treatment by autologous stem cell transplantation.

@article{Clements1997ChoosingAP,
  title={Choosing appropriate patients with systemic sclerosis for treatment by autologous stem cell transplantation.},
  author={Philip J. Clements and Daniel e. Furst},
  journal={The Journal of rheumatology. Supplement},
  year={1997},
  volume={48},
  pages={85-8}
}
Systemic sclerosis (SSc) with diffuse cutaneous scleroderma and visceral organ involvement is associated with considerable morbidity and mortality almost from its inception. Since the risk of accrual and progression of skin and organ complications is greatest in the first few years of SSc, the best opportunity for significantly modifying the course of SSc (prolonging survival and/or preventing or lessening the progressivity of organ involvement) is probably limited to the first 3 to 4 years… CONTINUE READING